phase III clinical study

Dec 13, 2022

Amgen to Seek Blincyto Approval in MRD-Negative ALL Following Positive Phase III Results
Premium

Dec 8, 2022

Circulating Tumor Cell-Guided Treatment Improves Outcomes for Some Breast Cancer Patients
Premium

Dec 5, 2022

GlaxoSmithKline Eyes Regulatory Filing After Positive Phase III Jemperli Data in Endometrial Cancer

Dec 5, 2022

Novartis to Seek Pluvicto Approval in Another Advanced PSMA-Positive Prostate Cancer Setting

Nov 29, 2022

Alaunos Therapeutics Expecting $15.7M in Common Stock Offering

Nov 29, 2022

Genentech to Withdraw First-Line Tecentriq Bladder Cancer Indication

Nov 22, 2022

Kintara Therapeutics Hopes to Fill Treatment Gap in Glioblastoma With VAL-083
Premium

Nov 17, 2022

Takeda to Discuss Positive Phase III Iclusig Data in Upfront ALL With Regulators

Nov 7, 2022

Telix Pharmaceuticals to Seek Marketing Approval in US, Abroad for TLX250-CDx

Oct 25, 2022

Pluvicto Sales Ramp up, Kisqali Gains Continue in Q3 for Novartis
Premium

Oct 18, 2022

Gilead Sciences Nets Second-Line Yescarta Approval for Lymphoma Patients in Europe

Oct 14, 2022

EMA's CHMP Recommends Novartis' Pluvicto for PSMA-Positive mCRPC

Oct 4, 2022

Research Clarifies Immunotherapy, Targeted Treatment Order for BRAF-Mutant Melanoma Patients
Premium

Oct 3, 2022

Clovis Oncology to File sNDA for Rubraca in BRCA1/2-Mutant Prostate Cancer

Sep 29, 2022

Atara Biotherapeutics to Net $30M From Pierre Fabre for European Tab-Cel Approval

Sep 20, 2022

Gradalis' Autologous Immunotherapy Shows Promise in Certain Ovarian Cancer Patients
Premium

Sep 19, 2022

EMA's CHMP Recommends Gilead's Yescarta for Second-Line Lymphoma

Sep 13, 2022

Combination Trials Point to New Potential Treatment Strategies in Breast Cancer
Premium

Sep 11, 2022

TIL Therapy Bests Yervoy in Head-to-Head Melanoma Trial; Will It Reach Patients Without Pharma?
Premium

Sep 10, 2022

Lilly's Verzenio Extends Five-Year Breast Cancer Survival, Adds to Debate Over Best CDK4/6 Inhibitor